User Stats

Total reviews: 1
Level: Guru
Member Since: 14/02/2023

Profile Information

First name Harri
Last name Järveläinen
I have professional experience in:

Biotech, Cancer therapeutics, Clinical trials, Drug Delivery, Drug Discovery, Immunology, Medicine, Nanotechnology, Neurosciences, Oncology, Personalised medicine, Therapeutics

Help us confirm that you're an expert

Drug hunter with a track record of more than 50 development programs, incl. small molecules, recombinant proteins, peptides and biologicals – from discovery into late clinical development in multiple therapeutic areas. Built and transformed a San Diego -based academic startup into a clinical-stage biotech Cend Therapeutics, with the lead peptide product CEND-1 being tested in multiple clinical trials (operating the company into Phase 2 as the only FTE of the company 2017-2020). Cend was listed in Nasdaq as Lisata Therapeutics ($LSTA) in September 2022. Big pharma experience from AstraZeneca, toxicology project lead and portfolio management within Respiratory / Inflammation (Lund, Sweden) and CNS / Pain research areas (Montreal, Canada).

Veterinary Medicine and PhD degrees from University of Helsinki, postdoctoral training at New York University Medical Center (New York, NY) and Max Planck Institute (Berlin, Germany). MBA degree from the University of New South Wales. Adjunct Professor of Toxicology at University of Helsinki since 2004. An author of >40 peer-reviewed scientific publications, patents, book chapters. Toxicology board certification toxicology from the US (DABT) and EU (ERT).

Specialties: Drug discovery and development, oncology, solid tumors, cancer, CNS, gastrointestinal, IND, preclinical, clinical, toxicology, GLP, executive, pharmaceuticals, biologicals, peptides, pharmacology, management, Beijing, China, San Diego, Australia, Singapore, CEO, COO, CSO

LinkedIn

http://www.linkedin.com/in/pharmaentrepreneur

Base
Name

Harri Järveläinen

I have professional experience in:

Biotech, Cancer therapeutics, Clinical trials, Drug Delivery, Drug Discovery, Immunology, Medicine, Nanotechnology, Neurosciences, Oncology, Personalised medicine, Therapeutics

Help us confirm that you're an expert

Drug hunter with a track record of more than 50 development programs, incl. small molecules, recombinant proteins, peptides and biologicals – from discovery into late clinical development in multiple therapeutic areas. Built and transformed a San Diego -based academic startup into a clinical-stage biotech Cend Therapeutics, with the lead peptide product CEND-1 being tested in multiple clinical trials (operating the company into Phase 2 as the only FTE of the company 2017-2020). Cend was listed in Nasdaq as Lisata Therapeutics ($LSTA) in September 2022. Big pharma experience from AstraZeneca, toxicology project lead and portfolio management within Respiratory / Inflammation (Lund, Sweden) and CNS / Pain research areas (Montreal, Canada).

Veterinary Medicine and PhD degrees from University of Helsinki, postdoctoral training at New York University Medical Center (New York, NY) and Max Planck Institute (Berlin, Germany). MBA degree from the University of New South Wales. Adjunct Professor of Toxicology at University of Helsinki since 2004. An author of >40 peer-reviewed scientific publications, patents, book chapters. Toxicology board certification toxicology from the US (DABT) and EU (ERT).

Specialties: Drug discovery and development, oncology, solid tumors, cancer, CNS, gastrointestinal, IND, preclinical, clinical, toxicology, GLP, executive, pharmaceuticals, biologicals, peptides, pharmacology, management, Beijing, China, San Diego, Australia, Singapore, CEO, COO, CSO

LinkedIn

http://www.linkedin.com/in/pharmaentrepreneur